Chemical and biological effects of substitution of the 2-position of ring-expanded ('fat') nucleosides containing the imidazo[4,5-e][1,3]diazepine-4,8-dione ring system: The role of electronic and steric factors on glycosidic bond stability and anti-HCV activity

Bioorganic and Medicinal Chemistry

Volumn 15, Issue 14, 2007, Pages 4933-4945

  Zhang, Peng ^a   Zhang, Ning ^a   Buckwold, Victor E ^b   Hosmane, Ramachandra S ^a  

^a UNIVERSITY OF MARYLAND BALTIMORE COUNTY   (United States)

^b SOUTHERN RESEARCH INSTITUTE   (United States)

Author keywords

2 Substituents; Anti HCV activity; Effects on glycosidic bond stability; Imidazo 4,5 e 1,3 diazepines; Ring expanded nucleoside analogues; Synthesis

Indexed keywords

6 N AMINO 7,8 DIHYDRO 2 (3 METHOXYPHENYL) 1 BETA DEXTRO RIBOFURANOSYLIMIDAZO[4,5 E][1,3]DIAZEPINE 4,8 DIONE; 6 N AMINO 7,8 DIHYDRO 2 (4 FLUOROPHENYL) 1 BETA DEXTRO RIBOFURANOSYLIMIDAZO[4,5 E][1,3]DIAZEPINE 4,8 DIONE; 6 N AMINO 7,8 DIHYDRO 2 (4 METHOXYPHENYL) 1 BETA DEXTRO RIBOFURANOSYLIMIDAZO[4,5 E][1,3]DIAZEPINE 4,8 DIONE; ANTIVIRUS AGENT; NUCLEOSIDE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DEGLYCOSYLATION; DRUG POTENCY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; NONHUMAN; RING CLOSING METATHESIS; RNA REPLICATION; SUBSTITUTION REACTION;

ANTIVIRAL AGENTS; AZEPINES; CELL LINE; ELECTRONS; GLYCOSIDES; HEPACIVIRUS; HUMANS; IMIDAZOLES; MOLECULAR STRUCTURE; NUCLEOSIDES; STRUCTURE-ACTIVITY RELATIONSHIP; VIRUS REPLICATION;

HEPATITIS C VIRUS; HUMAN ECHOVIRUS 1;

EID: 34249677814     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2007.04.043     Document Type: Article

References (21)

1. Zhang N., Chen H.-M., Koch V., Schmitz H., Liao C.-L., Bretner M., Bhadti V.S., Fattom A.I., Naso R.B., Hosmane R.S., and Borowski P. J. Med. Chem. 46 (2003) 4149-4164
2. Zhang N., Chen H.-M., Koch V., Schmitz H., Minczuk M., Stepien P., Fattom A.I., Naso R.B., Kalicharran K., Borowski P., and Hosmane R.S. J. Med. Chem. 46 (2003) 4776-4789
3. Diamond M.S., and Klein R.S. Trends Microbiol. 14 (2006) 287-289
4. Davis L.E., DeBiasi R., Goade D.E., Haaland K.Y., Harrington J.A., Harnar J.B., Pergam S.A., King M.K., DeMasters B.K., and Tyler K.L. Ann. Neurol. 60 (2006) 286-300
5. Hayes E.B., and Gubler D.J. Annu. Rev. Med. 57 (2006) 181-194
6. Dufour D.R. Molecular Diagnostics. 2nd ed. (2006), Humana Press, Totowa, NJ pp 461-471
7. Toniutto P., Fabris C., and Pirisi M. Expert. Opin. Pharmacother. 7 (2006) 2025-2035
8. MacDonald A., and Harris M. Liver Dis. 2 (2006) 439-458
9. Neyts J. Antiviral. Res. 71 (2006) 363-371
10. Huang Z., Murray M.G., and Secrist J.A. Antiviral. Res. 71 (2006) 351-362
11. Pol S., and Mallet V.O. Expert. Opin. Biol. Ther. 6 (2006) 923-933
12. Kim J., Morgenstern K., Griffith J., Dwyer J., and Thomson M.e.a. Structure 6 (1998) 89-100
13. Hodgman T.C. Nature 333 (1988) 22-23
14. Zhang P., Zhang N., Korba B.E., and Hosmane R.S. Bioorg. Med. Chem. Lett. 15 (2005) 5397-5401
15. Schomaker J.M., and Delia T.J. J. Org. Chem. 66 (2001) 7125-7128
16. Saladino R., Crestini C., Ciciriello F., Mauro E.D., and Costanzo G. J. Biol. Chem. 281 (2006) 5790-5796
17. Claire S. Nucleoside Mimetics: Their Chemistry and Biological Properties Vol. 1 (2001), Gordon and Breach Science, Amsterdam
18. Vorbrüggen H., and Bennua B. Chem. Ber. 114 (1981) 1279-1286
19. Vorbrüggen H., Krolikiewicz K., and Bennua B. Chem. Ber. 114 (1981) 1234-1255
20. Buckwold V.E., Wei J., Huang Z., Huang C., Nalca A., Wells J., Russell J., Collins B., Ptak R., Lang W., Scribner C., Blanchett D., Alessi T., and Langecker P. Antiviral Res. 73 (2007) 118-125. http://niaid-aacf.org/protocols/HCV.htm For details of HCV assay used, see AACF website: http://niaid-aacf.org/protocols/HCV.htm.
21. Krieger N., Lohmann V., and Bartenschlager R. J. Virol. 75 (2001) 4614-4624